60 completed, 12 recruiting, 9 unknown, 5 terminated. 93 Phase 1, 17 Phase 2.
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-04-01 | 2026-07-30 |
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer Psilocybin-assisted Psychotherapy - Demoralization, Safety | Phase 1 | Recruiting | Gustavo Vazquez | 15 | 2026-04-01 | 2026-03-18 |
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule Pasireotide cartridge with reusable ServoPen, Pasireotide ampule with syringe - Pharmacokinetics, Safety | Phase 1 | Completed | RECORDATI GROUP | 40 | 2025-12-01 | 2026-02-04 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy - Efficacy, Safety | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 132 | 2025-09-29 | 2025-08-19 |
| Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells - Spinal Cord Injury, Safety | Phase 1 | Recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 12 | 2025-07-02 | 2025-11-25 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) GenSci134, Placebo, Recombinant Human Growth Hormone Injection (Norditropin®) - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 64 | 2025-06-09 | 2026-04-14 |
| Purified Exosome Product (PEP) Injected Into the Hypodermis PEP (Purified Exosome Product) - Safety | Phase 1 | Completed | Clinical Testing of Beverly Hills | 8 | 2025-04-14 | 2025-12-26 |
| Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. Placebo (SAD), RCS-21 (SAD), Placebo (MD) - Healthy Volunteers, Safety | Phase 1 | Recruiting | RNATICS GmbH | 32 | 2025-02-18 | 2026-10-26 |
| A Phase 1 Study of Y-3 in US Healthy Volunteers. Y-3 for injection, Placebo - Safety, Tolerability | Phase 1 | Completed | Neurodawn Pharmaceutical Co., Ltd. | 20 | 2025-02-04 | 2025-12-18 |
| Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil - Healthy Volunteer, Pharmacokinetics | Phase 1 | Recruiting | Basilea Pharmaceutica | 96 | 2025-01-07 | 2026-11-05 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Teslanbaicin in Patients With Radiation Proctitis A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis, Teslanbai oral therapy - Safety | Phase 1 / Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Xinxiang Medical College | 29 | 2024-10-15 | 2025-05-15 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease GenSci098, GenSci098 Placebo - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 76 | 2024-09-24 | 2026-02-11 |
| Evaluation of Ascorbate-Meglumine Therapeutic for SRS Ascorbate-Meglumine - Safety | Phase 1 | Unknown | LadeRx LLC | 12 | 2024-09-09 | 2024-09-19 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
Showing 20 of 93. Sign in to see all of them.
COVID-19 (3) · Drug-Related Side Effects and Adverse Reactions (2) · Marijuana Abuse (2) · Respiratory Aspiration (2) · Stroke (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Corneal Diseases (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Dwarfism, Pituitary (1) · Glioblastoma (1) · Graves Disease (1) · Graves Ophthalmopathy (1)
Nervous System Diseases (7) · Central Nervous System Diseases (6) · Brain Diseases (5) · Respiratory Tract Diseases (5) · Chemically-Induced Disorders (4) · Infections (4) · Autoimmune Diseases (3) · Coronaviridae Infections (3) · Coronavirus Infections (3) · Endocrine System Diseases (3) · Eye Diseases (3) · Immune System Diseases (3) · Lung Diseases (3) · Mental Disorders (3) · Nidovirales Infections (3)
AZD9977 (2) · Injections (2) · Suspensions (2) · 3-((methylsulfonyl)amino)-2-phenyl-N-(1-phenylpropyl)quinolin-4-carboxamide (1) · 5-amino-2-((1-n-propyl-1H-imidazol-4-yl)methyl)pentanoic acid (1) · ACT-462206 (1) · ASP3652 (1) · AZD-3043 (1) · AZD3839 (1) · AZD9819 (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Anastrozole (1) · Ascorbic Acid (1) · Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1)
AstraZeneca (11) · Changchun GeneScience Pharmaceutical Co., Ltd. (5) · MicuRx (3) · Pfizer (3) · Sichuan Huiyu Pharmaceutical Co., Ltd (3) · The Affiliated Hospital of Qingdao University (3) · Astellas Pharma Europe B.V. (2) · CannaXan GmbH (2) · Hangzhou Yirui Pharmaceutical Technology Co., Ltd (2) · MedImmune LLC (2) · Shanghai Juncell Therapeutics (2) · Actelion (1) · Actinogen Medical (1) · Alan Richardson (1) · Alembic Pharmaceuticals Ltd. (1)
United States (24) · China (17) · United Kingdom (13) · Germany (9) · Belgium (3) · Canada (3) · Australia (2) · Bulgaria (2) · Denmark (2) · France (2) · Japan (2) · Netherlands (2) · Spain (2) · Sweden (2) · Italy (1)
Sharon L Hillier, PhD (2) · Ali R Djalilian, MD (1) · Axel Mescheder, MD (1) · Bill Ketelbey, MD (1) · Brendan Smyth (1) · Carin Jorup, MD (1) · Charlotte E Joslin, OD, PhD (1) · Chen Yu, MD (1) · Christopher M Burton, MD; PhD (1) · Darren Wilbraham (1) · David P Sonne, MD; PhD (1)
PMID 12750546, PMID 31601801, PMID 32087818, PMID 32715381, PMID 33148815, PMID 34487721, PMID 35789594, PMID 36028897, PMID 37185136, PMID 37832977, PMID 38258274, PMID 39727283, PMID 39858024, PMID 40693391, PMID 41293254, PMID 41456040, PMID 42419896, PMID 42644287, PMID 42648772
2015 (4), 2017 (2), 2009 (1), P30CA047904 (1), R44AG067907 (1), U19AI120249 (1)